Revising ecological assumptions about Human papillomavirus interactions and type replacement

Journal of Theoretical Biology

Volumn 350, Issue , 2014, Pages 98-109

  Murall, Carmen Lía ^a   McCann, Kevin S ^a   Bauch, Chris T ^b  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

HPV; Metapopulation dynamics; Strain interactions; Strain replacement; Within host ecology

Indexed keywords

ECOLOGICAL APPROACH; IMMUNE RESPONSE; METAPOPULATION; NUMERICAL MODEL; POPULATION DYNAMICS; SEXUALLY TRANSMITTED DISEASE; VACCINATION; VIRAL DISEASE;

ARTICLE; CONTROLLED STUDY; ECOLOGICAL NICHE; ENVIRONMENTAL FACTOR; IMMUNE RESPONSE; INNATE IMMUNITY; INTRASPECIFIC COMPETITION; MATHEMATICAL MODEL; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; VACCINATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS IDENTIFICATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIABILITY; WART VIRUS; CLASSIFICATION; ENVIRONMENTAL ASPECTS AND RELATED PHENOMENA; EPIDERMIS; HUMAN; IMMUNOLOGY; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; TIME; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

WART VIRUS VACCINE;

COINFECTION; ECOLOGICAL AND ENVIRONMENTAL PHENOMENA; EPIDERMIS; HUMANS; IMMUNITY, INNATE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; VIRAL LOAD;

EID: 84897963186     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.12.028     Document Type: Article

References (75)

1. Amarasekare P. Competitive coexistence in spatially structured environments: a synthesis. Ecol. Lett. 2003, 6:1109-1122.
2. Amarasekare P. Competition and coexistence: animals. The Princeton Guide to Ecology 2009, 196-201. Princeton University Press, New Jersey. S.A. Levin (Ed.).
3. Asquith B., Edwards C.T.T., Lipsitch M., McLean A.R. Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol. 2006, 4:e90.
4. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005, 32(Suppl. 1):S16-S24.
5. Bell G. Neutral macroecology. Science 2001, 80(293):2413-2418.
6. Bosch F.X., Castellsagué X., de Sanjosé S. HPV and cervical cancer: screening or vaccination?. Br. J. Cancer 2008, 98:15-21.
7. Carter J.R., Ding Z., Rose B.R. HPV infection and cervical disease: a review. Aust. N. Z. J. Obstet. Gynaecol. 2011, 51:103-108.
8. Castle P.E., Rodriguez A.C., Porras C., Herrero R., Schiffman M., Gonzalez P., Hildesheim A., Burk R.D. A comparison of cervical and vaginal human papillomavirus. Sex. Transm. Dis. 2007, 34:849-855.
9. Chase J.M., Leibold M.A. Ecological Niches: Classical and Contemporary Approaches 2003, The University of Chicago Press, Chicago.
10. Chase J.M., Myers J.A. Disentangling the importance of ecological niches from stochastic processes across scales. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2011, 366:2351-2363.
11. Chaturvedi A.K., Katki H.A., Hildesheim A., Rodríguez A.C., Quint W., Schiffman M., Van Doorn L.-J., Porras C., Wacholder S., Gonzalez P., Sherman M.E., Herrero R. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J. Infect. Dis. 2011, 203:910-920.
12. Chesson P. Mechanisms of maintance of species diversity. Annu. Rev. Ecol. Syst. 2000, 31:343-366.
13. Christensen N., Bounds C. Cross-protective responses to human papillomavirus infection. Future Virol. 2010, 5:163.
14. Christensen N.D., Koltun W.A., Cladel N.M., Budgeon L.R., Reed C.A., Kreider J.W., Welsh P.A., Patrick S.D., Irol J.V Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft. J. Virol. 1997, (71):7337-7344.
15. De Boer R., Oprea M., Antia R., Murali-krishna K., Ahmed R., Perelson A.S. Recruitment times, proliferation, and apoptosis rates during the CD8+ T-cell response to lymphocytic choriomeningitis virus. J. Virol. 2001, 35:10663-10669.
16. Dillner J., Arbyn M., Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 2010, 163:17-25.
17. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32(Suppl.):S7-15.
18. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., Stanley M.a The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30(Suppl. 5):F55-F70.
19. Elbasha E.H., Galvani A.P. Vaccination against multiple HPV types. Math. Biosci. 2005, 197:88-117.
20. Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T., Smith J.F., Macmullen S., Esser M.T., Paliard X. Priming of Human Papillomavirus Type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. 2002, 76:7832.
21. Gandon S., Day T. Evidences of parasite evolution after vaccination. Vaccine 2008, 26:C4-C7.
22. Garnett G.P., Waddell H.C. Public health paradoxes and the epidemiological impact of an HPV vaccine. J. Clin. Virol. 2000, 19:101-111.
23. Gravel D., Canham C.D., Beaudet M., Messier C. Reconciling niche and neutrality: the continuum hypothesis. Ecol. Lett. 2006, 9:399-409.
24. Hadzisejdć I., Krasević M., Haller H., Grahovac B. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll. Antropol. 2007, 31(Suppl. 2):97-102.
25. Holt R.D. Emergent neutrality. Trends Ecol. Evol. 2006, 21:531-533.
26. Hubbell S.P. A Unified Neutral Theory of Biodiversity and Biogeography 2001, Princeton University Press, Princeton, NJ.
27. Husband B.C., Barrett S.C.H. A metapopulation perspective in plant population biology. J. Ecol. 1996, 84:461-469.
28. Kaasila M., Koskela P., Kirnbauer R., Pukkala E., Surcel H.-M., Lehtinen M. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int. J. Cancer 2009, 125:2166-2172.
29. Kahn J.A., Brown D.R., Ding L., Widdice L.E., Shew M.L., Glynn S., Bernstein D.I. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130:1-8.
30. Kines R.C., Thompson C.D., Lowy D.R., Schiller J.T., Day P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20458-20463.
31. Klausmeier C.A., Tilman D. Spatial models of competition. Competition and Coexistence 2002, 43. Springer, Verlag Berlin Heidelberg. U. Sommer, B. Worm (Eds.).
32. Levin S., Pimentel D. Selection of intermediate rates of increase in parasite-host systems. Am. Nat. 1981, 117:308-315.
33. Levins R. Some demographic and genetic consequences of environmental heterogeneity for biological control. Bull. Entomol. Soc. Am. 1969, 15:237-240.
34. Levins R., Culver D. Regional coexistence of species and competition between rare species. Proc. Natl. Acad. Sci. 1971, 68:1246-1248.
35. Lipsitch M., Colijn C., Cohen T., Hanage W.P., Fraser C. No coexistence for free: neutral null models for multistrain pathogens. Epidemics 2009, 1:2-13.
36. Mariani L., Venuti A. HPV vaccine[U+202F]: an overview of immune response, clinical protection, and new approaches for the future. J. Transl. Med. 2010, 8:105.
37. Martcheva M., Bolker B.M., Holt R.D. Vaccine-induced pathogen strain replacement: what are the mechanisms?. J. R. Soc. Interface 2008, 5:3-13.
38. McGill B.J., Maurer B.a, Weiser M.D. Empirical evaluation of neutral theory. Ecology 2006, 87:1411-1423.
39. McLaughlin-Drubin M.E., Meyers C. Evidence for the coexistence of two genital HPV types within the same host cell in vitro. Virology 2004, 321:173-180.
40. Mendez F., Munoz N., Posso H., Molano M., Moreno V., van den Brule A.J.C., Ronderos M., Meijer C., Munoz A. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 2005, 192:1158-1165.
41. Merikukka M., Kaasila M., Namujju P.B., Palmroth J., Kirnbauer R., Paavonen J., Surcel H.-M., Lehtinen M. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int. J. Cancer 2011, 128:1114-1119.
42. Mideo N. Parasite adaptations to within-host competition. Trends Parasitol. 2009, 25:261-268.
43. Mideo N., Barclay V.C., Chan B.H.K., Savill N.J., Read A.F., Day T. Understanding and predicting strain-specific patterns of pathogenesis in the rodent malaria Plasmodium chabaudi. Am. Nat. 2008, 172:214-238.
44. Murall C.L., McCann K.S., Bauch C.T. Food webs in the human body: linking ecological theory to viral dynamics. PLoS One 2012, 7:e48812.
45. Nowak M.A., May R.M. Superinfection and the evolution of parasite virulence. Proc. R. Soc. B Biol. Sci. 1994, 255:81-89.
46. Palmroth J., Merikukka M., Paavonen J., Apter D., Eriksson T., Natunen K., Dubin G., Lehtinen M. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int. J. Cancer 2012, 000:1-7.
47. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., García-Piñeres A.J., Trivett M., Demuth F., Lowy D.R., Schiller J.T., Berzofsky J.A., Hildesheim A. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006, 353:451-462.
48. Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., Wheeler C.M. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J. Infect. Dis. 2007, 195:1582-1589.
49. Plummer M., Vaccarella S., Franceschi S. Multiple human papillomavirus infections: the exception or the rule?. J. Infect. Dis. 2011, 203:891-893.
50. Poolman E.M., Elbasha E.H., Galvani A.P. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine 2008, 26:C25-C30.
51. Quint W., Jenkins D., Molijn A., Struijk L., van de Sandt M., Doorbar J., Mols J., Van Hoof C., Hardt K., Struyf F., Colau B. One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J. Pathol. 2012, 227:62-71.
52. Rosindell J., Hubbell S.P., He F., Harmon L.J., Etienne R.S. The case for ecological neutral theory. Trends Ecol. Evol. 2012, 27:204-209.
53. Rositch A.F., Hudgens M.G., Backes D.M., Moses S., Agot K., Nyagaya E., Snijders P.J.F., Meijer C.J.L.M., Bailey R.C., Smith J.S. Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men. J. Infect. Dis. 2012, 206(5):1-9.
54. Rousseau M.C., Pereira J.S., Prado J.C., Villa L.L., Rohan T.E., Franco E.L. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J. Infect. Dis. 2001, 184:1508-1517.
55. Rousseau M.C., Villa L.L., Cecilia Costa M., Abrahamowicz M., Rohan T.E., Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex. Transm. Dis. 2003, 30:581.
56. Schiller J.T., Castellsagué X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl. 1):K53-K61.
57. Schiller J.T., Day P.M., Kines R.C. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 2010, 118:S12-S17.
58. Schiller J.T., Lowy D.R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 2012, 10:681-692.
59. Schmitt M., Dondog B., Waterboer T., Pawlita M., Tommasino M., Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol. 2010, 48:143-149.
60. Spinillo A., Dal Bello B., Alberizzi P., Cesari S., Gardella B., Roccio M., Silini E.M. Clustering patterns of human papillomavirus genotypes in multiple infections. Virus Res. 2009, 142:154-159.
61. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 1:16-22.
62. Stanley M. HPV - immune response to infection and vaccination. Infect. Agent. Cancer 2010, 5:19.
63. Stanley M., Lowy D.R., Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006, 24(Suppl. 3):S3/106-13. (Chapter 12).
64. Thomas K.K., Hughes J.P., Kuypers J.M., Kiviat N.B., Lee S., Adam D.E., Koutsky L.A. Concurrent and sequential acquisition of different genital human papillomavirus types. Society 2000, 182:1097-1102.
65. Tilman D. Resource Competition and Community Structure 1982, vol.17. Princeton University Press, Princeton, N.J. Ed.
66. Tota, J.E., Agnihotram, R.V., Coutlée, F., Villa, L.L., Richardson, H., Burchell, A., Koushik, A., Mayrand, M.H., Franco, E.L., 2011a. Epidemiologic approach to evaluate potential for HPV type replacement post-vaccination. In: Proceedings of the 27th International Papillomavirus Conference and Clinical Workshop.
67. Tota J.E., Chevarie-Davis M., Richardson L.A., DeVries M., Franco E.L. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev. Med. 2011, 53:S12-S21.
68. Tota J.E., Ramanakumar A.V, Jiang M., Dillner J., Walter S.D., Kaufman J.S., Coutlée F., Villa L.L., Franco E.L. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am. J. Epidemiol. 2013, 178:625-634.
69. Trottier H., Mahmud S., Prado J.C.M., Sobrinho J.S., Costa M.C., Rohan T.E., Villa L.L., Franco E.L. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis. 2008, 197:1436-1447.
70. Weinberg A., Song L.-Y., Saah A., Brown M., Moscicki A.B., Meyer W.a, Bryan J., Levin M.J. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J. Infect. Dis. 2012, 206:1309-1318.
71. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., Salmerón J., Chow S.-N., Apter D., Kitchener H., Teixeira J.C., Skinner S.R., Jaisamrarn U., Limson G., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.a J., Bosch F.X., Harper D.M., Huh W., Hardt K., Zahaf T., Descamps D., Struyf F., Dubin G., Lehtinen M. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13:100-110.
72. Williams O., Hart K., Wang E., Gelder C. Analysis of CD4+ T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J. Virol. 2002, 76:7418.
73. Woodman C.C.B.J., Collins S.S.I., Young L.L.S. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 2007, 7:11-22.
74. Xi L.F., Edelstein Z.R., Meyers C., Ho J., Cherne S.L., Schiffman M. Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol. Biomark. Prev. 2009, 18:2507-2512.
75. Yates A., Graw F., Barber D.L., Ahmed R., Regoes R.R., Antia R. Revisiting estimates of CTL killing rates in vivo. PLoS One 2007, 2:e1301.